← FDA DRUG APPROVALS

FDA NDA · NDA208855

VERZENIO

Sponsor: ELI LILLY AND CO

APPLICATION
NDA208855
TYPE
NDA
ORIGINAL APPROVAL
2018-02-26
LATEST ACTION
2018-02-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

VERZENIOPrescription
ABEMACICLIB 200MG · TABLET · ORAL
VERZENIOPrescription
ABEMACICLIB 100MG · TABLET · ORAL
VERZENIOPrescription
ABEMACICLIB 150MG · TABLET · ORAL
VERZENIOPrescription
ABEMACICLIB 50MG · TABLET · ORAL

Approval history

2018-02-26Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →